South Korea's Celltrion Group has begun a long-awaited merger process for three of its affiliates – Celltrion, Inc., Celltrion Healthcare Co., Ltd. and Celltrion Pharm Inc. – to create synergies and corporate capabilities, with the strategic aim of growing into a global integrated biotech operation with total annual sales of KRW12tn ($9bn) by 2030.
Biosimilars And Beyond: Celltrion Aiming For $9bn Post Merger
Two-Phase Plan
After years of talks, Korea's Celltrion Group is finally moving ahead with the merger of three key affiliates aimed at improving cost competitiveness and securing investment resources, as well as simplifying transaction structures and improving governance.
